Comparative Pharmacology
Head-to-head clinical analysis: NICOTINE versus NICOTINE POLACRILEX ORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICOTINE versus NICOTINE POLACRILEX ORAL.
NICOTINE vs NICOTINE POLACRILEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine is a nicotinic acetylcholine receptor (nAChR) agonist; binds to α4β2 and α7 subtypes in the central nervous system, causing release of dopamine and other neurotransmitters, leading to stimulation and reward effects. Also acts on peripheral nicotinic receptors affecting autonomic ganglia, neuromuscular junction, and adrenal medulla.
Nicotine polacrilex acts as a nicotinic acetylcholine receptor agonist, binding to α4β2 receptors in the ventral tegmental area and mediating dopamine release in the nucleus accumbens, which reduces withdrawal symptoms and cravings by providing a lower and slower peak of nicotine compared to smoking.
Transdermal patch: 21 mg/24 hours applied to dry, non-hairy skin once daily; gum: 2-4 mg chewed as needed (max 24 pieces/day); lozenge: 2-4 mg dissolved as needed (max 20 lozenges/day); inhaler: 6-16 cartridges/day (each 4 mg delivered); nasal spray: 1-2 doses/hour (1 dose = 0.5 mg, 32 mg/day max).
2 mg or 4 mg lozenge or gum as needed up to 20 lozenges or pieces of gum per day; typical dosing: 1 lozenge or piece of gum every 1-2 hours while awake, up to 12 per day. For smoking cessation, initial dose based on smoking habits: if first cigarette within 30 minutes of waking, use 4 mg; if >30 minutes, use 2 mg.
Clinical Note
moderateNicotine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Nicotine."
Clinical Note
moderateNicotine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Nicotine."
Clinical Note
moderateNicotine + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Nicotine resulting in a loss in efficacy."
Clinical Note
moderateNone Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); short half-life leads to frequent dosing to maintain therapeutic effects.
The terminal elimination half-life of nicotine is approximately 2 hours (range 1-4 hours) after intravenous administration or smoking, but after polacrilex gum use, absorption is slower and half-life may be slightly prolonged due to continued absorption. Clinical context: short half-life necessitates frequent dosing to maintain levels for smoking cessation.
Primarily hepatic metabolism (80-90%) to cotinine and nicotine-N-oxide; renal excretion of unchanged nicotine accounts for 5-10% in non-smokers and up to 30% in smokers with acidic urine; less than 2% excreted in feces via biliary elimination.
Nicotine and its metabolites are primarily excreted renally. About 10-20% of nicotine is excreted unchanged in urine, with the remainder as metabolites, mainly cotinine. Urinary pH affects excretion; acidic urine increases clearance. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Smoking cessation aid
Smoking cessation aid
Nicotine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Nicotine."